|Performance evaluation and comparison of the newly developed Elecsys anti-HCV II assay with other widely used assays|
|Yang, Ruifeng; Guan, Wenli; Wang, Qian; Liu, Yan; Wei, Lai|
|关键词||Hepatitis c Virus Anti-hcv Elecsys Anti-hcv Ii Architect Anti-hcv Vitros Anti-hcv Genotype|
|刊名||CLINICA CHIMICA ACTA|
|WOS标题词||Science & Technology|
|类目[WOS]||Medical Laboratory Technology|
|研究领域[WOS]||Medical Laboratory Technology|
|关键词[WOS]||HEPATITIS-C VIRUS ; RECOMBINANT IMMUNOBLOT ASSAY ; HUMAN-IMMUNODEFICIENCY-VIRUS ; INFECTION ; GENOTYPES ; 2ND-GENERATION ; PREVALENCE ; CHINA|
Background: Anti-HCV assays remain the first choice for screening HCV infection in most clinical laboratories. The Elecsys anti-HCV II assay has been recently launched and we aimed to evaluate its performance compared with other widely used methods.
Methods: Four seroconversion panels, 861 consecutive sera under routine clinical conditions, 100 preselected sera with low positive anti-HCV results and 178 samples from patients infected with HIV were tested using Elecsys anti-HCV II, Architect anti-HCV and Vitros anti-HCV assays. Confirmatory testing was performed using RIBA and HCV RNA tests. Moreover, 203 samples with different HCV genotypes were assessed using Elecsys anti-HCV H.
Results: Elecsys anti-HCV II detected seroconversion 7-14 days earlier than the Architect and Vitros assays. Furthermore, it had 100% sensitivity and superior specificity in screening routine clinical samples, including those with low positive anti-HCV, and detected 97.6% (122/125) anti-HCV-positive samples from HIV-infected patients with HCV viremia. However, the anti-HCV levels in the genotype 3b samples were slightly underestimated.
Conclusions: Elecsys anti-HCV II shortens the seroconversion window. It is suitable for screening HCV infection in clinical samples, including those from immunocompromised patients, due to the excellent sensitivity and specificity. Further investigation of the subtype inclusivity in a larger sample number might be warranted. (C) 2013 Elsevier B.V. All rights reserved.
|项目编号||2008ZX10002-012 ; 2008ZX10002-013 ; 2012ZX10002003 ; RDC2012-06|
|资助机构||National Science and Technology Major Project for Infectious Diseases Control ; Peking University People&prime ; s Hospital Research and Development Funds|
|作者单位||Peking Univ, Peoples Hosp, Inst Hepatol, Beijing Key Lab Hepatitis & Immunotherapy Liver D, Beijing 100044, Peoples R China|
|Yang, Ruifeng,Guan, Wenli,Wang, Qian,et al. Performance evaluation and comparison of the newly developed Elecsys anti-HCV II assay with other widely used assays[J]. CLINICA CHIMICA ACTA,2013,426:95-101.|
|APA||Yang, Ruifeng,Guan, Wenli,Wang, Qian,Liu, Yan,&Wei, Lai.(2013).Performance evaluation and comparison of the newly developed Elecsys anti-HCV II assay with other widely used assays.CLINICA CHIMICA ACTA,426,95-101.|
|MLA||Yang, Ruifeng,et al."Performance evaluation and comparison of the newly developed Elecsys anti-HCV II assay with other widely used assays".CLINICA CHIMICA ACTA 426(2013):95-101.|